GC Green Cross Unveils "Real-Time Bioprocess Monitoring Model"

Scalable from Small-Scale Laboratories to Large-Scale Manufacturing Processes

GC Green Cross announced on September 29 that it delivered a presentation at BMK 2025, held at Songdo Convensia from the 25th to the 26th, on the topic of "Development of a Real-Time Bioprocess Monitoring and Prediction System Using Raman Spectroscopy."

Cha Kyungil, Head of MSAT Division at GC Green Cross, presenting at BMK2025. GC Green Cross

BMK 2025, the largest bioprocessing conference in Korea, serves as a platform to share the latest trends in drug development, production, and commercialization processes for biologics, antibody-drug conjugates (ADC), and cell and gene therapies (CGT).

At this event, GC Green Cross introduced a process monitoring model utilizing an automated micro-cultivation system and Raman spectroscopy. This model enables real-time prediction of six key metabolites-including glucose, lactate, and glutamine-during the cultivation process without the need for sampling. In addition, a model transfer strategy was developed to extend its application to manufacturing scale.

In particular, the company improved metabolite prediction errors by up to 55% compared to previous methods by implementing a model transfer approach that overcomes spectral variations and differences in mixing efficiency between bioreactors during scale-up. As a result, the model is expected to be swiftly applied not only in research stages but also in actual large-scale production environments.

This model was developed as part of GC Green Cross's digital-based process innovation strategy, aiming to strengthen smart manufacturing capabilities. The company expects that this technology will contribute to advanced real-time quality control and improved production efficiency during new drug development.

Cha Kyungil, Head of the MSAT Division at GC Green Cross, who led the presentation, stated, "We will optimize process efficiency through scalable and robust prediction models," adding, "We will continue to drive process innovation that meets global regulatory standards."

This content was produced with the assistance of AI translation services.